



Attorney Docket No.: 6454.504-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hansen et al.

Serial No.: 10/602,340

Group Art Unit: To be assigned

Filed: June 23, 2003

Examiner: To be assigned

For: Liquid Composition of Modified Factor VII Polypeptides

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (12)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on September 15, 2003

Dolly Kapadia  
(name of person mailing paper)

Dolly Kapadia  
(signature of person mailing paper)

Attorney Docket No.: 6454.504-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hansen et al.

Application No.: 10/602,340

Group Art Unit: To be assigned

Filed: June 23, 2003

Examiner: To be assigned

For: Liquid Composition of Modified Factor VII Polypeptides

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. U.S. Patent no. 4,297,344
2. U.S. Patent no. 5,770,700
3. U.S. Patent Application Publication No. US 2001/0031721 A1
4. WO 92/15686


5. WO 94/26286
6. WO 94/27631
7. WO 96/12800
8. WO 97/19687
9. WO 97/47651
10. Manning et al., Pharmaceutical Research, Vol. 6, No. 11, pages 903-918 (1989)
11. Cleland et al., Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 10, No. 4, pages 307-377 (1993)
12. Wang et al., Journal of Parenteral Science & Technology, Vol. 42, pages S2-S26 (1988)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: September 15, 2003

Respectfully submitted,



Reza Green, Reg. No. 38,475  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449  
(Rev. 2-2001)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6454.504-US

Serial No. 10/602,340

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Applicant Hansen et al.

(Use several sheets if necessary)

Filing Date June 23, 2003

Group To be assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,297,344	10/27/81	Schwinn et al.	424	101	
	5,770,700	6/23/98	Webb et al.	530	383	
	Pub. No. US 2001/0031721 A1	10/18/01	Webb et al.	514	2	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 92/15686 A1	9/17/92	PCT				
	WO 94/26286 A1	11/24/94	PCT				
	WO 94/27631 A1	12/8/94	PCT				
	WO 96/12800 A1	5/2/96	PCT				
	WO 97/19687 A1	6/5/97	PCT				
	WO 97/47651 A1	12/18/97	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Manning et al., Pharmaceutical Research, Vol. 6, No. 11, pages 903-918 (1989)
		Cleland et al., Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 10, No. 4, pages 307-377 (1993)
		Wang et al., Journal of Parenteral Science & Technology, Vol. 42, pages S2-S26 (1988)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.